Brainsway (NASDAQ:BWAY) Sets New 1-Year High - What's Next?

Key Points

• Shares of Brainsway hit a new 52-week high of $16.80 (last trade $16.819) and are trading above their 50‑day ($14.00) and 200‑day ($11.09) moving averages, giving the company a market cap of about $674.5M.
• Analyst sentiment has turned positive with several upgrades (Zacks to strong‑buy, Wall Street Zen and Weiss to buy), though the consensus price target is $15.00, below the current share price.
• Brainsway beat quarterly estimates with EPS of $0.14 versus $0.11 expected and revenue of $14.55M versus $14.02M, and analysts forecast full‑year EPS of $0.31.

Shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY - Get Free Report) reached a new 52-week high on Friday . The stock traded as high as $16.80 and last traded at $16.8190, with a volume of 15032 shares trading hands. The stock had previously closed at $16.56.

Wall Street Analyst Weigh In

Several research firms have recently commented on BWAY. Northland Securities set a $15.00 price target on shares of Brainsway in a report on Thursday, January 22nd. HC Wainwright dropped their price objective on shares of Brainsway from $30.00 to $15.00 and set a "buy" rating on the stock in a research note on Thursday, March 12th. Zacks Research upgraded Brainsway from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, March 24th. Wall Street Zen raised Brainsway from a "hold" rating to a "buy" rating in a report on Saturday, March 7th. Finally, Weiss Ratings upgraded Brainsway from a "hold (c)" rating to a "buy (b-)" rating in a research report on Friday, April 24th. One equities research analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the stock. According to data from MarketBeat.com, Brainsway has an average rating of "Buy" and a consensus target price of $15.00.

Brainsway Price Performance

The stock has a fifty day moving average price of $14.00 and a two-hundred day moving average price of $11.09. The company has a market cap of $674.51 million, a P/E ratio of 67.39 and a beta of 1.10.

Brainsway (NASDAQ:BWAY - Get Free Report) last issued its quarterly earnings data on Wednesday, March 11th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.11 by $0.03. The business had revenue of $14.55 million during the quarter, compared to analyst estimates of $14.02 million. Brainsway had a return on equity of 11.10% and a net margin of 14.62%. As a group, analysts forecast that Brainsway Ltd. Sponsored ADR will post 0.31 earnings per share for the current year.

Institutional Investors Weigh In On Brainsway

Hedge funds and other institutional investors have recently modified their holdings of the stock. Raymond James Financial Inc. bought a new position in Brainsway in the 2nd quarter valued at about $85,000. Bank of America Corp DE acquired a new stake in shares of Brainsway in the 3rd quarter worth approximately $107,000. Royal Bank of Canada lifted its stake in shares of Brainsway by 1,145.9% in the 4th quarter. Royal Bank of Canada now owns 8,410 shares of the company's stock worth $160,000 after acquiring an additional 7,735 shares during the period. Centiva Capital LP bought a new position in shares of Brainsway in the third quarter valued at approximately $181,000. Finally, NewEdge Advisors LLC increased its stake in shares of Brainsway by 61.5% during the first quarter. NewEdge Advisors LLC now owns 19,828 shares of the company's stock valued at $188,000 after acquiring an additional 7,549 shares during the period. 30.11% of the stock is currently owned by institutional investors.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway's technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company's flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.